Carrying on with liver transplantation during the COVID-19 emergency: Report from Piedmont region by Saracco, M. et al.
ARTICLE IN PRESS+ModelCLINRE-1512; No. of Pages 6
Clinics and Research in Hepatology and Gastroenterology (2020) xxx, xxx—xxx




Carrying  on  with  liver  transplantation
during  the  COVID-19  emergency:  Report
from  piedmont  region
Margherita  Saraccoa,1,  Silvia  Martini a,∗,1,  Francesco  Tandoib,
Dominic  Dell’Olioc,  Antonio  Ottobrelli a,  Antonio  Scarmozzinod,
Antonio  Amorosoc,  Paolo  Fonioe,
Roberto  Balagnaf,  Renato  Romagnoli b
a Gastrohepatology  Unit,  AOU  Città  della  Salute  e  della  Scienza  di  Torino,  University  of  Turin,  Turin,  Italy
b General  Surgery  2U,  Liver  Transplantation  Center,  AOU  Città  della  Salute  e  della  Scienza  di  Torino,
University  of  Turin,  Turin,  Italy
c Regional  Transplantation  Center,  Piedmont,  AOU  Città  della  Salute  e  della  Scienza  di  Torino,  University  of
Turin, Turin,  Italy
d Molinette  Hospital,  AOU  Città  della  Salute  e  della  Scienza  di  Torino,  Turin,  Italy
e Radiology  Unit,  AOU  Città  della  Salute  e  della  Scienza  di  Torino,  University  of  Turin,  Turin,  Italy






Background:  The  COVID-19  pandemic  is  an  emergency  worldwide.  In  Italy,  liver  transplant  activ-
ity was  carried  on,  but  despite  all  efforts,  a  25%  reduction  of  procured  organs  has  already  been
observed  during  the  first  4  weeks  of  the  outbreak.
Aims:  To  analyze  if  our  strategy  and  organization  of  LT  pathway  during  the  first  two  months  ofPlease  cite  this  article  in  press  as:  Saracco  M,  et  al.  Carrying  on  with  liver  transplantation  during  the  COVID-19  emergency:
Report  from  piedmont  region.  Clin  Res  Hepatol  Gastroenterol  (2020),  https://doi.org/10.1016/j.clinre.2020.07.017
Tertiary  healthcare;
Team  working the COVID-19  emergency  succeeded  in  keeping  a  high  level  of  LT  activity,  comparing  the  number
of LT  in  the  first  two  months  with  the  same  period  of  time  in  2019.
Methods:  We  compared  the  liver  transplants  performed  in  our  Center  between  February  24th
and April  17th,  2020  with  liver  transplants  performed  in  the  same  period  in  2019.
Abbreviations: AIH, autoimmune hepatitis; ALF, acute liver failure; ASSLD, American Association for the Study of Liver Disease; BAL,
bronchoalveolar lavage; CIT, cold ischemia time; CNT, Italian Transplant Authority; EAD, early allograft dysfunction; EASL, European Asso-
ciation for the Study of the Liver; HCC, hepatocellular carcinoma; HOPE, Hypothermic Oxygenated Machine Perfusion; ICU, intensive care
unit; LT, liver transplant; MELD, Model for the End-stage Liver Disease; NASH, non-alcoholic steatohepatitis; NPS, nasopharyngeal swab;
WHO, World Health Organization.
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Results:  In  2020,  21  patients  underwent  liver  transplantation  from  deceased  donors,  exactly
as the  year  before,  without  statistically  significant  difference.  All  patients  survived  in  both
groups, and  the  rate  of  early  graft  dysfunction  was  24%  in  2020  and  33%  in  2019.  In  2020  Median
MELD was  higher  (17  vs  13).  We  were  able  to  perform  3  multiorgan  transplants  and  one  acute
liver failure.  Nobody  died  on  waiting  list.  The  performance  of  our  Center,  despite  the  maxi-
emergency  situation,  was  steady  and  this  was  the  result  of  a  tremendous  team  working  within
the hospital  and  in  our  region.
Conclusions:  Team  working  allowed  our  Center  to  maintain  its  activity  level,  taking  care  of
patients  before  and  after  liver  transplantation.  Sharing  our  experience,  we  hope  to  be  helpful
to other  Centers  that  are  facing  the  pandemic  and,  if  another  pandemic  comes,  to  be  more
prepared  to  deal  with  it.








































































he  COVID-19  pandemic  caused  by  SARS-CoV-2  virus  is  a
ublic  health  emergency  affecting  all  aspects  of  medical
are.  On  January  30th,  2020,  the  World  Health  Organiza-
ion  (WHO)  declared  it  to  be  a  global  health  emergency  and
ince  March  13th  Europe  became  the  epicenter  of  the  pan-
emic.  By  the  end  of  February  2020,  Italy  had  experienced  a
apid  spread  of  the  virus,  starting  from  its  Northern  regions,
ith  a  daily  increase  in  the  number  of  cases  and  deaths.
n  February  24th,  2020  a  WHO-led  team  of  experts  arrived
n  Italy  in  order  to  assist  the  local  health  authorities.  On
he  8th  of  March  the  Italian  government  instituted  a con-
ainment  red  zone  enclosing  the  most  affected  areas  and  in
he  following  days  further  decrees  extended  strict  lockdown
easures  to  the  whole  country  in  order  to  contrast  SARS-
oV-2  spread.  All  non-urgent  and  non-oncological  activities
ere  suspended  in  national  health  service  hospitals  and
lanned  surgeries  were  postponed.  A  growing  number  of
ards  and  intensive  care  unit  (ICU)  beds  were  quickly  ded-
cated  to  the  care  of  COVID-19  patients.  On  April  17th,  in
taly  there  were  172.434  confirmed  cases,  42.727  healed  and
2.745  deaths  and  the  Piedmont  alone  counted  450  cases
er  100.000  inhabitants  with  19.803  confirmed  cases,  3.634
ealed  and  2.171  deaths  [1].  According  to  the  European
ssociation  for  the  Study  of  the  Liver  (EASL)  [2]  and  Amer-
can  Association  for  the  Study  of  Liver  Disease  (AASLD)  [3]
iver  transplant  (LT)  activity,  as  an  acute  care  treatment,
hould  not  be  postponed,  even  in  the  COVID-19  era.  Prelimi-
ary  data  in  post-LT  patients  [4,5]  did  not  show  an  increased
isk  of  severe  COVID-19  disease,  despite  immunosuppression
ay  prolong  viral  shedding  [6].  Cirrhotic  patients  might  be
ore  susceptible  to  virus  infection  because  of  their  dysfunc-
ional  immune  response  and  transplantation  in  SARS-CoV-2
ositive  recipients  is  currently  not  recommended  [2,3].
onsequently,  the  Italian  Transplant  Authority  (CNT)  recom-
ends  that  all  pauci/symptomatic  recipients  and  all  donors
ught  to  be  tested  for  SARS-CoV-2  RNA  (nasopharyngealPlease  cite  this  article  in  press  as:  Saracco  M,  et  al.  Carrying  on  
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wab,  NPS  or  bronchoalveolar  lavage,  BAL)  [7]  immediately
re-LT  and  those  who  test  positive  are  to  be  considered  med-
cally  ineligible  for  transplantation/donation;  screening  of





ocal  resources  availability.  Despite  all  efforts  to  preserve
ransplant  activity,  a  25%  reduction  of  procured  organs  has
lready  been  observed  in  Italy  during  the  first  4 weeks  of  the
utbreak  [8].
Our  working  hypothesis  is  that  our  organization  of  LT
athway  during  the  first  two  months  of  the  COVID-19  emer-
ency  succeeded  in  keeping  a  high  level  of  LT  activity,
espite  the  reduction  of  procured  organs.
We  aimed  to  analyze  the  number  of  LT  performed
etween  February  24th,  2020  and  April  17th,  2020  with  the
ame  period  of  time  in  2019,  in  our  high-volume  transplant
enter  (median  150  LT/year).
aterials and methods
tudy  population
n  this  observational  cohort  study,  we  consecutively  enrolled
ll  patients  who  underwent  LT  in  our  Center,  between  the
4th  of  February  2020  and  the  17th  of  April  2020.  In  addition,
e  retrospectively  analyzed  the  LTs  performed  in  2019,  in
he  same  period  of  time.  The  variables  assessed  in  the  study
opulation  and  their  donors  are  shown  in  Table  1.
Pursuant  to  Italian  law,  Regional  Transplantation  Centers
re  the  custodians  of  donor/recipient  biomedical  data  also
or  research  purposes.  All  study  procedures  complied  with
he  ethical  standards  of  the  2000  Declaration  of  Helsinki  and
he  Declaration  of  Istanbul  2008.
linical  protocol
y  the  end  of  February  2020,  the  number  of  patients  com-
ng  to  our  transplant  clinic  was  limited  to  subjects  with
rgent  issues  and  phone  visits  or  telemedicine  as  appro-
riate  replaced  in-person  appointments.  Arrival  times  were
taggered  in  order  to  avoid  patients  congregating  in  the
aiting  areas.  Before  entry,  all  patients  were  screened  forwith  liver  transplantation  during  the  COVID-19  emergency:
2020),  https://doi.org/10.1016/j.clinre.2020.07.017
OVID-19  symptoms  or  recent  exposure  and  each  patient’s
emperature  was  checked.  A  pre-triage  form  had  to  be
lled  out  before  every  procedure.  Outpatient  LT  diagnos-
ic  workups  were  carried  out  by  using  COVID-free  pathways.
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Table  1  Recipient  and  donor  characteristics.
2020  (n  =  21)  2019  (n  =  21)  P-value
Recipient  characteristics
Male  16  (76%)  15  (71%)  .99
Age, years 56  [51—65] 58  [56—62] .72
Etiology  of  cirrhosis .15
Viral  4  (20%)  11  (52%)
Alcoholic  7  (35%)  5  (24%)
AIH and  cholestatic  disorders  5  (25%)  1  (5%)
NASH 2  (10%)  1  (5%)
Others  2  (10%)  3  (14%)
Etiology  of  ALF
Viral  1  (5%)  0
HCC in  cirrhotic  patients  9  (45%)  8  (38%)  .75
Blood type  .63
A 12  (57%)  11  (52%)
B 2  (10%)  5  (24%)
AB 1  (5%)  1  (5%)
0 6  (29%)  4  (19%)
Multiple  organs  transplant  3  (14%)  1  (5%)  .61
MELD at  LT  17  [12—22]  13  [9—18]  .13
Donor characteristic
Age,  years  58  [38—72]  60  [51—63]  .45
Donor after  cardiac  death  1  (5%)  0  .99
Suboptimal graft  10  (48%)  7  (33%)  .53
Regional donors  18  (86%)  16  (76%)  .69
Transplant operation
Ex  vivo  machine  perfusion  4  (19%)a 6  (29%)  .72
Cold Ischemia  Time,  minutes  452  [346—473]  431  [393—495]  .99
Post-transplant  course
EAD  5  (24%)  7  (33%)  .73
ICU-stay, days  5  [4—7]  4  [3—6]  .69
Hospital-stay,  days  11  [10—17]  13  [8—21]  .82
Discharge home  20b (95%)  21  (100%)  1
Abbreviations: AIH, autoimmune hepatitis; EAD, early graft dysfunction, according to Olthoff; HCC, hepatocellular carcinoma; ICU,
















One out of four with normothermic machine perfusion.
b One still hospitalized (combined lung-liver-pancreas transplan
As  already  published,  we  recommended  to  our  patients  fre-
quent  handwashing  and  sanitization,  avoid  public  places  and
overcrowded  situations  and  wear  a  surgical  mask  to  prevent
of  SARS-CoV-2  infection  [9—11].
In  our  hospital  7  wards  (5  internal  medicine,  pneumology
and  cardiology),  4  out  of  5  ICUs  and  1  out  of  4  Radiology
Unit  were  progressively  dedicated  to  COVID  patients;  On
April  17th  in  the  district  of  Turin  there  were  9.503  confirmed
cases.
In  our  liver  sub-intensive  unit,  we  were  allowed  to  con-
tinue  to  admit  patients  with  severe  decompensated  liver
disease,  and  from  March  31st  every  patient  before  admission
was  tested  for  SARS-CoV-2  RNA  by  NPSs  in  order  to  guarantee
a  COVID-free  unit.  Furthermore,  among  the  5  intensive  care
units  of  our  hospital,  the  one  dedicated  to  transplants  was
maintained  COVID-free,  by  testing  each  transplant  recipientPlease  cite  this  article  in  press  as:  Saracco  M,  et  al.  Carrying  on  
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in  advance  with  SARS-CoV-2  RNA  in  NPS  or  BAL,  starting  from




The  only  source  of  our  donors  are  deceased  donors  after
rain  or  cardiac  death  and  all  of  them  were  screened  for
ARS-CoV-2,  according  to  CNT  guidelines.  A  deceased  donor
raft  was  defined  suboptimal  if  donor  age  was  ≥65  years
nd/or  had  macrovesicular  steatosis  ≥15%  [12].  The  degree
f  fatty  infiltration  of  the  graft  were  assessed  on  liver  biop-
ies  routinely  obtained  at  the  end  of  transplant  surgery.  In
ur  center,  from  2016,  grafts  from  brain  death  donors  cha-
acterized  by  increased  risk  profile  (donors  >80  years  and/or
bese  donors)  as  well  as  from  donors  after  cardiac  death
ndergo  Hypothermic  Oxygenated  Machine  Perfusion  (HOPE)
efore  implantation,  to  reduce  ischemia-reperfusion  injury.
ecently,  normothermic  machine  perfusion  (OrganOx)  was
lso  used.
After  LT,  immunosuppression  consisted  of  tacrolimus,with  liver  transplantation  during  the  COVID-19  emergency:
2020),  https://doi.org/10.1016/j.clinre.2020.07.017
ycophenolate  mofetil  and  steroids,  as  per  our  standard
rotocol.  Early  allograft  dysfunction  (EAD)  was  defined
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nternational  normalized  ratio  ≥1.6  on  postoperative  day  7
r  aspartate  aminotransferase  or  alanine  aminotransferase
evel  >2000  IU/L  within  the  first  7  days  after  transplant.
tatistical  analysis
ategorical  variables  were  represented  as  number  (n)  and
ercentage  (%)  and  compared  using  Fisher’s  exact  test
r  Chi-square  test.  Quantitative  variables  were  shown  as
edian  and  interquartile  range  (25th—75th  percentiles,  IQR)
nd  their  distribution  was  evaluated  with  D’Agostino  &
earson  test;  parametric  data  were  evaluated  by  t-test,  non-
arametric  data  were  evaluated  by  Mann—Whitney  U  test.
 <  0.05  in  a  two-tailed  test  was  considered  statistically  sig-
ificant.
esults
etween  February  24th,  2020  and  April  17th,  2020,  among
2  admissions  in  our  7-bed  sub-intensive  liver  unit,  a  40-
ear-old  woman,  who  was  listed  during  hospitalization,
eveloped  fever  during  hospitalization  and  tested  positive
or  SARS-CoV-2  RNA  in  NPSs.  Immediately  transferred  to  a
OVID  unit,  she  came  back  to  our  unit  after  7  days  and  2
egative  SARS-CoV-2  RNA  in  NPS  and  underwent  LT  the  day
fter  readmission  to  our  unit.
At  the  beginning  and  at  the  end  of  the  enrollment  period
1  and  52  patients,  respectively,  were  actively  on  the  LT
aiting  list.  None  of  the  patients  on  the  LT  waiting  list
ad  to  be  admitted  to  hospital  for  COVID-19  and  the  on-
ist  mortality  rate  was  0%.  During  the  study  period,  21  first
Ts  were  consecutively  performed  in  our  Center.  The  major-
ty  of  the  recipients  were  male,  with  a  median  age  of  56
ears  (IQR  51—65).  The  median  biochemical  Model  for  end-
tage  Liver  disease  (MELD)  at  LT  was  17  (IQR  12—22).  Twenty
atients  were  affected  by  cirrhosis  (20%  viral-,  35%  alcohol-,
5%  autoimmune/cholestatic-related)  and  45%  of  them  also
y  hepatocellular  carcinoma  (HCC).  Two  out  of  the  twenty
atients  underwent  combined  liver-kidney  transplant  and
ne  combined  lung-liver-pancreas  transplant.  One  patient
as  transplanted  for  HBV-related  acute  liver  failure  (ALF)
Table  1).  Four  out  of  21  patients  (19%)  were  hospitalized  at
he  time  of  LT  and  the  ALF  patient  was  in  the  ICU  on  venti-
ator/respiratory  support.  Looking  at  the  donors:  86%  of  the
raft  were  recruited  in  our  regional  area.  The  median  donor
ge  was  58  years  (IQR  38—72)  and  48%  of  the  grafts  were
uboptimal.  The  median  cold  ischemia  time  was  452  min
IQR  346—473).  Ex  vivo  normothermic  machine  perfusion
as  employed  for  one  graft,  and  hypothermic  perfusion  for
 grafts.  95%  of  livers  came  from  brain-dead  donors  and
ne  from  a  donor  after  cardiac  death.  After  LT,  1  out  of
he  21  recipients  was  found  positive  for  SARS-CoV2  on  NPS
n  his  5th  day  post-LT,  after  his  bed  neighbor,  who  was
ecovering  from  liver  resection,  had  tested  positive  the  day
efore.  His  oxygen  saturation  was  persistently  normal  and
T  scan  was  negative  for  pneumonia.  We  transferred  the
atient  immediately  to  the  COVID  unit,  where  precaution-Please  cite  this  article  in  press  as:  Saracco  M,  et  al.  Carrying  on  
Report  from  piedmont  region.  Clin  Res  Hepatol  Gastroenterol  (
ry  hydroxychloroquine  400  mg  twice  daily  was  administered
or  16  days.  Mycophenolate  mofetil  dosing  was  reduced  from
500  mg/day  to  1000  mg/day  and  target  tacrolimus  trough
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neventful  days  in  COVID  unit,  and  the  SARS-CoV2  on  NPS
s  still  positive,  without  specific  symptoms.
In  2019,  over  the  same  period  of  time,  at  the  beginning
nd  at  the  end  of  the  enrollment  period  60  and  71  patients,
espectively,  were  actively  on  the  LT  waiting  list;  the  mortal-
ty  rate  on  the  LT  waiting  list  was  0%  and  we  performed  the
ame  number  of  LTs  (19  first  transplant  and  2  re-transplants),
ompared  with  2020.  71%  of  the  patients  was  male,  with  a
edian  age  of  58  years  (IQR  56—62).  The  median  biochemi-
al  MELD  at  LT  was  13  (IQR  9—18)  with  an  HCC  rate  of  38%.
he  etiology  of  liver  cirrhosis  was  viral  for  52%  of  the  cases,
lcohol  related  for  24%.  The  median  donor  age  was  60  years
IQR  51—63),  all  of  them  were  brain-dead  and  76%  of  the
raft  were  recruited  into  our  regional  area.  The  median
old  ischemia  time  was  431  min  (IQR  393—495)  and  33%  of
he  grafts  were  suboptimal.  Ex-vivo  hypothermic  machine
erfusion  was  used  in  29%  of  the  grafts.
All  patients  survived  in  both  groups,  and  the  rate  of  EAD
as  24%  in  2020  and  33%  in  2019  (Table  1).  We  did  not  find  any
tatistically  significant  difference  between  the  two  cohorts.
iscussion
e  compared  LT  activity  in  our  Center  during  the  first  2
onths  of  COVID-19  pandemic,  starting  since  February  24th,
ith  the  same  period  of  the  year  before.  Italy  has  been  the
rst  European  country  to  face  the  severe  COVID-19  pandemic
ince  February  2020  and  our  National  Healthcare  System,
hich  offers  universal  access  to  health  care  to  all  residents,
s  facing  a tremendous  pressure.  Hospitals  and  health  work-
rs  were  asked  to  suspend  all  non-urgent  activities  and  to
ostpone  all  planned  surgery  in  order  to  give  over  beds  to  the
reatment  of  COVID-19  patients.  In  accordance  with  AASLD
nd  EASL  recommendations  [2,3],  transplant  surgery  was
xcluded  from  these  limitations,  in  order  not  to  compound
he  outbreak  lethality  with  risking  the  lives  of  patients  who
eed  a  life-saving  LT.  This  requires  stringent  criteria  for  pri-
ritizing  patients  who  are  more  likely  to  die  on  the  wait
ist  and  a delicate  balance  with  the  risk  of  hospital-acquired
OVID-19.  In  order  to  optimize  resource  utilization  and  to
void  transplantation  in  virus-positive  patients,  every  effort
as  been  made  to  prevent  SARS-CoV-2  infection  in  patients
efore  and  after  LT  and  the  SARS-CoV-2  molecular  screening
or  donors  and  symptomatic  recipients  became  mandatory.
In  our  Country  deceased  donors  are  the  prevalent  organ
esource  and  a restriction  in  the  number  of  available  ICU
eds  necessarily  influenced  the  donation  activity;  in  fact,
uring  the  first  4  weeks  of  COVID-19  outbreak  the  number
f  procured  organs  dropped  by  25%,  as  reported  by  CNT.
From  1990  more  than  3000  LTs  have  been  carried  out  at
ur  Center  and  the  annually  LT  volume  is  around  150.  The
nit  is  located  into  a  region  strongly  hit  by  COVID-19  (454
ases  per  100,000  inhabitants  and  50  deaths  per  100,000).
n  our  study  we  evidenced  that,  despite  the  emergency  pub-
ic  health  situation,  we  performed  during  the  first  2  months
he  same  number  of  LT  of  the  year  before,  without  mortality
n  the  waiting  list  and  early  post-transplant.  Median  MELDwith  liver  transplantation  during  the  COVID-19  emergency:
2020),  https://doi.org/10.1016/j.clinre.2020.07.017
as  higher  as  well  as  the  complexity  of  patients:  we  man-
ged  3  multiorgan  transplants  and  one  acute  liver  failure,
ithout  significantly  impacting  on  the  ICU  hospitalization
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2019,  P  =  0.69)  and  all  patients  survived  in  both  groups.  Fur-
thermore,  the  majority  of  the  donors  were  recruited  in  our
regional  area,  one  of  the  hardest  hits  by  the  virus,  and
we  were  able  to  manage  machine  perfusion  in  19%  of  the
cases  inside  our  hospital.  We  did  not  change  our  standard
immunosuppression  regimen,  according  to  published  data
which  show  that  immunosuppression  was  not  a  risk  factor
for  mortality  associated  with  SARS  (2002—2003)  or  MERS
(2012-present)  [3,4],  even  if  it  may  prolong  viral  shedding
in  post-transplant  patients  with  COVID-19  [3,6].
We  strongly  believe  that  the  steady  performance  of
our  Center,  despite  the  maxi-emergency  situation,  was  the
result  of  a  tremendous  team  working  within  the  hospi-
tal  and  in  the  Piedmont  Region.  Our  healthcare  Director
(AS)  rapidly  switched  in  our  tertiary  referral  hospital  many
medical  doctors  and  departments  previously  dedicated  to
different  specialties,  into  new  COVID-19  units,  progressively
increasing  in  number  and  size.  Our  transplant  hepatologists
were  spared  from  the  full-time  management  of  COVID-units,
in  order  to  take  care  of  outpatient  and  inpatient  transplant
patients.  Our  liver  sub-intensive  care  and  transplant  inten-
sive  unit  were  included  into  a  COVID-free  pathway  within
the  hospital  and  a  strong  collaboration  between  transplant
hepatologists  and  surgeons  made  possible  the  prioritization
of  patients  more  in  need  of  transplant  and  to  optimize  the
recipient/donor  match.  Furthermore,  regional  ICUs  were
able  to  preserve  beds  and  intensivists  for  the  management
of  a  precious  resource  like  a  potential  organ  donor.  Despite
all  our  efforts  to  maintain  a  transplant  COVID-free  pathway,
two  transplant  patients,  one  before  and  one  after  LT  were
tested  SARS-CoV-2  virus  positive  during  hospitalization  and
both  were  safely  discharged  home.
Some  limitations  need  to  be  acknowledged.  The  small
number  of  enrolled  patients,  limited  period  of  the  study
and  the  monocentric  experience.  The  experience  of  Maggi
et  al.  [14]  as  well  the  preliminary  analysis  of  Italian  Soci-
ety  for  Organ  Transplantation  [15]  showed  that  there  is  a
variability  in  the  emergency  management  even  between
the  Italian  regions.  Lombardy  has  10.002.615  inhabitants
[16]  and  four  active  liver  transplant  programs  (Ospedale
Niguarda  in  Milan,  Fondazione  IRCCS  Policlinico  in  Milan,  Isti-
tuto  dei  Tumori  in  Milan  and  Ospedali  Riuniti  in  Bergamo).
This  is  the  region  that  was  hit  first,  with  the  highest  number
of  cases  in  Italy  (On  April  17th  there  were  64.135  confirmed
cases  and  11.851  deaths,  641  cases/100.000  inhabitants).
Piedmont  has  4.392.526  inhabitants  [16]  and  the  liver  trans-
plant  activity  is  focused  in  a  single  center,  in  Turin.  The
COVID-19  outbreak  arrived  in  Piedmont  with  a  delay  of
around  two  weeks,  and  on  April  17th,  2020  19.803  con-
firmed  cases  and  2.171  deaths  were  recorded,  with  450
cases/100,000  inhabitants.  The  delay  of  the  epidemic  peak
and  the  centralization  of  LT  activity  could  explain  the  dif-
ferent  results  reported  from  the  Lombardy  centers  and  ours.
Agopian  et  al.  also  reported  a  great  variability  in  LT  activity
from  different  regions  in  US  [17].
In  conclusion,  Italy  is  facing  an  unprecedented  health
care  emergency  situation  due  to  the  COVID-19  pandemic.
Team  working  with  close  involvement  of  several  specialtiesPlease  cite  this  article  in  press  as:  Saracco  M,  et  al.  Carrying  on  
Report  from  piedmont  region.  Clin  Res  Hepatol  Gastroenterol  (
such  as  hepatologists,  surgeons,  anesthesiologists  and  radi-
ologists  allowed  our  single  regional  Center  to  maintain  its
activity  level,  taking  care  of  patients  before  and  after  LT.




ot  suspended  when  it  is  possible.  Sharing  our  experience,
e  hope  to  be  helpful  to  other  Transplant  Centers  that  are
ow  facing  the  COVID-19  emergency.
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